18 research outputs found
Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies.
Variation in steroid hormone levels has wide implications for health and disease. The genes encoding the proteins involved in steroid disposition represent key determinants of interindividual variation in steroid levels and ultimately, their effects. Beginning with metabolomic data from genome-wide association studies (GWAS), we observed that genetic variants in the orphan transporter, SLC22A24 were significantly associated with levels of androsterone glucuronide and etiocholanolone glucuronide (sentinel SNPs p-value <1x10-30). In cells over-expressing human or various mammalian orthologs of SLC22A24, we showed that steroid conjugates and bile acids were substrates of the transporter. Phylogenetic, genomic, and transcriptomic analyses suggested that SLC22A24 has a specialized role in the kidney and appears to function in the reabsorption of organic anions, and in particular, anionic steroids. Phenome-wide analysis showed that functional variants of SLC22A24 are associated with human disease such as cardiovascular diseases and acne, which have been linked to dysregulated steroid metabolism. Collectively, these functional genomic studies reveal a previously uncharacterized protein involved in steroid homeostasis, opening up new possibilities for SLC22A24 as a pharmacological target for regulating steroid levels
AI is a viable alternative to high throughput screening: a 318-target study
: High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy is sufficient to identify useful molecules. Through the largest and most diverse virtual HTS campaign reported to date, comprising 318 individual projects, we demonstrate that our AtomNet® convolutional neural network successfully finds novel hits across every major therapeutic area and protein class. We address historical limitations of computational screening by demonstrating success for target proteins without known binders, high-quality X-ray crystal structures, or manual cherry-picking of compounds. We show that the molecules selected by the AtomNet® model are novel drug-like scaffolds rather than minor modifications to known bioactive compounds. Our empirical results suggest that computational methods can substantially replace HTS as the first step of small-molecule drug discovery
Recommended from our members
Structure, Function, and Druggability of SLC Transporters and Kinases
All functions of a protein involve its physical interactions, however transient, with specific other molecules (ligands), large or small. Protein structure and its dynamics, determined by sequence, in turn determine which molecules are able to bind to the protein. Druggable proteins are defined as those whose function can be modulated with a small molecule. The contents of this dissertation focus on leveraging the knowledge about protein structure and changes in protein structure to identify small molecule modulators of protein function, thus expanding the druggable proteome. The studied proteins include members of the kinase and SLC transporter superfamilies, both important drug targets. First, we separately examine the impact of mutations on the structures of two kinases, FLT3 and BCR-ABL, and the resistance of these mutants to drugs. We provide a structure-based rationale for the cause of resistance and offer treatment alternatives. Second, we address the modulation of function of human organic cation transporters (OCTs), either through phosphorylation or structure-guided screens to discover novel small molecule inhibitors of these transporters. We establish that by combining docking and in vitro high-throughput screens, competitive and non-competitive ligands of OCTs can be predicted accurately. Third, we examine the quaternary structure of the human concentrative nucleoside transporters (CNTs) to gain new insight into their functions and use structure-guided screens to discover novel ligands to modulate them. We show that human concentrative nucleoside transporter 3 forms homo-oligomers, thus encouraging efforts on finding allosteric inhibitors. Finally, we present a large-scale study of the impact of cancer mutations on protein structure, with the hope of expanding the druggable proteome through the discovery of mutant-specific binding pockets that would allow for selective, functional inhibition or activation
Recommended from our members
Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer
Many anticancer and
antiviral drugs are purine or pyrimidine analogues,
which use membrane transporters to cross cellular membranes. Concentrative
nucleoside transporters (CNTs) mediate the salvage of nucleosides
and the transport of therapeutic nucleoside analogues across plasma
membranes by coupling the transport of ligands to the sodium gradient.
Of the three members of the human CNT family, CNT3 has the broadest
selectivity and the widest expression profile. However, the molecular
mechanisms of the transporter, including how it interacts with and
translocates structurally diverse nucleosides and nucleoside analogues,
are unclear. Recently, the crystal structure of vcCNT showed that
the prokaryotic homologue of CNT3 forms a homotrimer. In this study,
we successfully expressed and purified the wild type human homologue,
hCNT3, demonstrating the homotrimer by size exclusion profiles and
glutaraldehyde cross-linking. Further, by creating a series of cysteine
mutants at highly conserved positions guided by comparative structure
models, we cross-linked hCNT3 protomers in a cell-based assay, thus
showing the existence of hCNT3 homotrimers in human cells. The presence
and absence of cross-links at specific locations along TM9 informs
us of important structural differences between vcCNT and hCNT3. Comparative
modeling of the trimerization domain and sequence coevolution analysis
both indicate that oligomerization is critical to the stability and
function of hCNT3. In particular, trimerization appears to shorten
the translocation path for nucleosides across the plasma membrane
and may allow modulation of the transport function via allostery
Recommended from our members
Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3
Human OAT1 and OAT3 play major roles in renal drug elimination and drug-drug interactions. However, there is little information on the interactions of drug metabolites with transporters. The goal of this study was to characterize the interactions of drug metabolites with OAT1 and OAT3 and compare their potencies of inhibition with those of their corresponding parent drugs. Using HEK293 cells stably transfected with OAT1 and OAT3, 25 drug metabolites and their corresponding parent drugs were screened for inhibitory effects on OAT1-and OAT3-mediated 6-carboxyfluorescein uptake at a screening concentration of 200 μM for all but 3 compounds. 20 and 24 drug metabolites were identified as inhibitors (inhibition > 50%) of OAT1 and OAT3, respectively. Seven drug metabolites were potent inhibitors of either or both OAT1 and OAT3 with Ki values less than 1 μM. 22 metabolites were more potent inhibitors of OAT3 than OAT1. Importantly, one drug and four metabolites were predicted to inhibit OAT3 at unbound plasma concentrations achieved clinically (Cmax,u/Ki values ≥ 0.1). In conclusion, our study highlights the potential interactions of drug metabolites with OAT1 and OAT3 at clinically relevant concentrations, suggesting that drug metabolites may modulate therapeutic and adverse drug response by inhibiting renal drug transporters
Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer
Many anticancer and
antiviral drugs are purine or pyrimidine analogues,
which use membrane transporters to cross cellular membranes. Concentrative
nucleoside transporters (CNTs) mediate the salvage of nucleosides
and the transport of therapeutic nucleoside analogues across plasma
membranes by coupling the transport of ligands to the sodium gradient.
Of the three members of the human CNT family, CNT3 has the broadest
selectivity and the widest expression profile. However, the molecular
mechanisms of the transporter, including how it interacts with and
translocates structurally diverse nucleosides and nucleoside analogues,
are unclear. Recently, the crystal structure of vcCNT showed that
the prokaryotic homologue of CNT3 forms a homotrimer. In this study,
we successfully expressed and purified the wild type human homologue,
hCNT3, demonstrating the homotrimer by size exclusion profiles and
glutaraldehyde cross-linking. Further, by creating a series of cysteine
mutants at highly conserved positions guided by comparative structure
models, we cross-linked hCNT3 protomers in a cell-based assay, thus
showing the existence of hCNT3 homotrimers in human cells. The presence
and absence of cross-links at specific locations along TM9 informs
us of important structural differences between vcCNT and hCNT3. Comparative
modeling of the trimerization domain and sequence coevolution analysis
both indicate that oligomerization is critical to the stability and
function of hCNT3. In particular, trimerization appears to shorten
the translocation path for nucleosides across the plasma membrane
and may allow modulation of the transport function via allostery
Recommended from our members
Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies
The human solute carrier 22A (SLC22A) family consists of 23 members, representing one of the largest families in the human SLC superfamily. Despite their pharmacological and physiological importance in the absorption and disposition of a range of solutes, eight SLC22A family members remain classified as orphans. In this study, we used a multifaceted approach to identify ligands of orphan SLC22A15. Ligands of SLC22A15 were proposed based on phylogenetic analysis and comparative modeling. The putative ligands were then confirmed by metabolomic screening and uptake assays in SLC22A15 transfected HEK293 cells. Metabolomic studies and transporter assays revealed that SLC22A15 prefers zwitterionic compounds over cations and anions. We identified eight zwitterions, including ergothioneine, carnitine, carnosine, gabapentin, as well as four cations, including MPP+ , thiamine, and cimetidine, as substrates of SLC22A15. Carnosine was a specific substrate of SLC22A15 among the transporters in the SLC22A family. SLC22A15 transport of several substrates was sodium-dependent and exhibited a higher Km for ergothioneine, carnitine, and carnosine compared to previously identified transporters for these ligands. This is the first study to characterize the function of SLC22A15. Our studies demonstrate that SLC22A15 may play an important role in determining the systemic and tissue levels of ergothioneine, carnosine, and other zwitterions
Recommended from our members
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
Organic cation transporter 1 (OCT1) plays a critical role in the hepatocellular uptake of structurally diverse endogenous compounds and xenobiotics. Here we identified competitive and noncompetitive OCT1-interacting ligands in a library of 1780 prescription drugs by combining in silico and in vitro methods. Ligands were predicted by docking against a comparative model based on a eukaryotic homologue. In parallel, high-throughput screening (HTS) was conducted using the fluorescent probe substrate ASP+ in cells overexpressing human OCT1. Thirty competitive OCT1 ligands, defined as ligands predicted in silico as well as found by HTS, were identified. Of the 167 ligands identified by HTS, five were predicted to potentially cause clinical drug interactions. Finally, virtual screening of 29 332 metabolites predicted 146 competitive OCT1 ligands, of which an endogenous neurotoxin, 1-benzyl-1,2,3,4-tetrahydroisoquinoline, was experimentally validated. In conclusion, by combining docking and in vitro HTS, competitive and noncompetitive ligands of OCT1 can be predicted